The Biggest Psychedelic News This Week – October 2nd
Psychedelic news: PTSD treatments, Esketamine’s efficacy, Eureka’s decrim, and PsyCan’s proposal. Stay informed on the latest updates.
Psychedelic news: PTSD treatments, Esketamine’s efficacy, Eureka’s decrim, and PsyCan’s proposal. Stay informed on the latest updates.
Psychedelic News: California’s Bill 58 updates, SSRIs and DMT for depression, Maine’s pivotal moments, and Brazil’s opinions on psychedelics.
Psychedelic News Surge: Massachusetts’ Plant Medicine Dive, Kentucky’s Ibogaine Initiative, Pain-Relieving Potential, and Ketamine’s Pediatric Promise
California stands on the cusp of a psychedelic revolution with the TREAT Act and a landmark bill on ‘magic mushrooms,’ even as Michigan, Congress, and global initiatives from Sweden to Canada expand the horizons of mental health, addiction treatment, and veteran care.
Progress on Psychedelic Legalization Accelerates Across U.S. with Key Developments in Massachusetts, California, and Federal Policy Outreach
Colorado Advances Psychedelic Legalization with Public Input, Cybin Inc. Acquires Small Pharma, and New Studies Highlight Efficacy of Psilocybin Therapy for Cancer and Depression.
Red Light Holland’s psilocybin capsules clear stability tests for Australian distribution, as new research explores psychedelics’ impact on neural synchronization and consciousness, while Oregon’s psilocybin therapy shows promising mental health benefits-but don’t expect insurance coverage just yet.
Minnesota’s psychedelics task force faces delays; APPA & BrainFutures release first guidelines for psychedelic therapy; Nevada hesitates on magic mushroom decriminalization; “Myco Method” psilocybin program gets second state warning.
Massachusetts is pushing for legalization on the 2024 ballot, a move that could change the game. A recent study has found intriguing parallels between psychedelic and near-death experiences, deepening our understanding of these substances. Despite a shrinking stock universe, the field is buzzing with potential, especially with new insights into how psychedelics impact our brain and social cognition. However, federal laws are blocking further research due to Schedule I restrictions.
Michael Pollan provides insights into the current psychedelic landscape. Minneapolis mayor unilaterally deprioritizes entheogen-related arrests. Synthetic psilocybin-assisted therapy shows promise in treating anorexia nervosa.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.